![Robert A. Heft](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert A. Heft
Directeur/Membre du Conseil chez
CLEMENTIA PHARMACEUTICALS INC
Profil
Robert A. Heft was the founder of IBEX Technologies, Inc. (founded in 1972) where he held the title of President, Director & Chief Scientist from 1972 to 2001.
He currently holds the position of Independent Director at Lumos Pharma Sub, Inc., Independent Director at Clementia Pharmaceuticals, Inc., and Director at Parvus Therapeutics, Inc. He previously held positions such as President, Chief Executive Officer & Director at Enobia Pharma, Inc. from 2010 to 2012, Chief Executive Officer & Director at Zingenix Ltd. from 2014 to 2019, and Chairman at Eloxx Pharmaceuticals Ltd. He has also served as a Director at VisionGate, Inc., Ra Pharmaceuticals, Inc., Biocapital Investments Ltd, Canadian Genetic Disease Network, and Industrial Biotechnology Association of Canada.
Additionally, he was Vice President-Product Development at BioMarin Pharmaceutical, Inc. from 2001 to 2004 and Executive-in-Residence at Sectoral Asset Management, Inc. He obtained his undergraduate degree from McGill University, a doctorate from Massachusetts Institute of Technology in 1986, and a graduate degree from Cornell University.
Postes actifs de Robert A. Heft
| Sociétés | Poste | Début |
|---|---|---|
| CLEMENTIA PHARMACEUTICALS INC | Directeur/Membre du Conseil | 01/06/2013 |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Develops and commercializes a novel treatment for the rare disease Creatine Transporter Deficiency | Directeur/Membre du Conseil | - |
Parvus Therapeutics, Inc.
 Parvus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells biopharmaceutical products | Directeur/Membre du Conseil | - |
Anciens postes connus de Robert A. Heft
| Sociétés | Poste | Fin |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 02/04/2020 |
Zingenix Ltd.
 Zingenix Ltd. BiotechnologyHealth Technology Provides gene therapy for orphan disorders | Directeur Général | 01/03/2019 |
| ELOXX PHARMACEUTICALS, INC. | Président | 27/12/2017 |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for bone disorders | Directeur Général | 01/02/2012 |
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/01/2004 |
Formation de Robert A. Heft
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
78
Relations au 1er degré
18
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 18 |
|---|---|
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
IBEX Technologies, Inc.
 IBEX Technologies, Inc. Pharmaceuticals: OtherHealth Technology Produces proprietary enzymes and reagents for diagnostic tests | Health Technology |
VisionGate, Inc.
 VisionGate, Inc. Medical SpecialtiesHealth Technology Develops non-intrusive testing, AI-powered cancer detection and patented Cell-CT imaging devices | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
Sectoral Asset Management, Inc.
 Sectoral Asset Management, Inc. Investment ManagersFinance Sectoral aims to achieve superior returns for their investors by concentrating on primary research of company fundamentals and in-depth due diligence on companies to assess their scientific, business, financial and ESG aspects. The firm offers four Healthcare strategies: Global Healthcare, Emerging Healthcare, Small & Mid-Cap Healthcare & Biotech. They employ a bottom-up investment approach that can be categorized as Growth at a Reasonable Price (GARP). | Finance |
Biocapital Investments Ltd
 Biocapital Investments Ltd Investment Banks/BrokersFinance Manages assets in the healthcare and biotechnology industries | Finance |
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for bone disorders | Health Technology |
Canadian Genetic Disease Network | |
Industrial Biotechnology Association of Canada | |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Develops and commercializes a novel treatment for the rare disease Creatine Transporter Deficiency | Health Services |
Eloxx Pharmaceuticals Ltd.
 Eloxx Pharmaceuticals Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel genetic therapies | Health Technology |
Clementia Pharmaceuticals, Inc.
 Clementia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops treatments for patients suffering from bone disorders and other diseases | Health Technology |
Zingenix Ltd.
Zingenix Ltd. BiotechnologyHealth Technology Provides gene therapy for orphan disorders | Health Technology |
Parvus Therapeutics, Inc.
Parvus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells biopharmaceutical products | Health Technology |
Eloxx Pharmaceuticals, Inc.
 Eloxx Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that discovers and develops therapeutics to treat cystic fibrosis, inherited retinal disorders and other diseases | Health Technology |
